Tags

Type your tag names separated by a space and hit enter

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases.
SAGE Open Med Case Rep. 2017; 5:2050313X17692936.SO

Abstract

OBJECTIVES

The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported.

METHODS

We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved.

RESULTS

In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case.

CONCLUSIONS

We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis.

Authors+Show Affiliations

Gakuji-Kai Kimura Hospital, Chiba, Japan; Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan.Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba, Japan; Division of Medical Treatment and Rehabilitation, Center for Forensic Mental Health, Chiba University, Chiba, Japan.Gakuji-Kai Kimura Hospital, Chiba, Japan.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

28255444

Citation

Muneoka, Katsumasa, et al. "Switching to Aripiprazole for the Treatment of Residual Mutism Resulted in Distinct Clinical Courses in Two Catatonic Schizophrenia Cases." SAGE Open Medical Case Reports, vol. 5, 2017, p. 2050313X17692936.
Muneoka K, Kanahara N, Kimura S. Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases. SAGE open medical case reports. 2017;5:2050313X17692936.
Muneoka, K., Kanahara, N., & Kimura, S. (2017). Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases. SAGE Open Medical Case Reports, 5, 2050313X17692936. https://doi.org/10.1177/2050313X17692936
Muneoka K, Kanahara N, Kimura S. Switching to Aripiprazole for the Treatment of Residual Mutism Resulted in Distinct Clinical Courses in Two Catatonic Schizophrenia Cases. SAGE open medical case reports. 2017;5:2050313X17692936. PubMed PMID: 28255444.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases. AU - Muneoka,Katsumasa, AU - Kanahara,Nobuhisa, AU - Kimura,Shou, Y1 - 2017/02/08/ PY - 2016/07/29/received PY - 2017/01/13/accepted PY - 2017/3/4/entrez PY - 2017/3/4/pubmed PY - 2017/3/4/medline KW - Mutism KW - aripiprazole KW - catatonia KW - dopamine supersensitivity psychosis SP - 2050313X17692936 EP - 2050313X17692936 JF - SAGE open medical case reports VL - 5 N2 - OBJECTIVES: The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. METHODS: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. RESULTS: In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case. CONCLUSIONS: We will discuss the benefits and risks of using aripiprazole for the treatment of catatonic schizophrenia and the possibility of dopamine supersensitivity psychosis. SN - 2050-313X UR - https://www.unboundmedicine.com/medline/citation/28255444/Switching_to_aripiprazole_for_the_treatment_of_residual_mutism_resulted_in_distinct_clinical_courses_in_two_catatonic_schizophrenia_cases_ L2 - https://journals.sagepub.com/doi/10.1177/2050313X17692936?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.